FDA approves BondEase skin adhesive for closure of incisions and lacerations- OptMed Inc.

OptMed Inc.,a medical device manufacturer, announced that the Company received 510(k) marketing clearance from the FDA for its BondEase product, a topical skin adhesive intended for the closure of surgical incisions and lacerations as an alternative to sutures and staples. BondEase is a biocompatible, topical skin adhesive that combines a novel polymer technology with a user-friendly delivery device.

Comment: Biosurgical adhesives are rapidly emerging as important alternatives to sutures and staples to achieve rapid wound closure, reduce surgical treatment time and costs, protect from infections, and improve cosmetic results. These products are used widely in the emergency and operating room settings. The global market for high-strength medical adhesives is forecast to show strong double-digit growth over the next several years, growing from roughly $713 million in 2011 to $1.72 billion by 2017.